A reminder.... From the CEO RIK. I've had private companies in the dietary supplement space for the last 25 years. In this case, I actually brought this into Nutra Pharma to consolidate FDA requirements but also improve Nutra Pharma revenues. This was my gift to Nutra Pharma and our stakeholders to add additional value while we're building out the rest of our business plan.
Thinking logically, the Board just approved my additional 8M preferred shares (which I paid through the conversion of almost $500K). Why would I bother if my plan was to abscond with the IP. In all honesty, I'm the biggest shareholder and larger debtor to the company. I could have shut everything down and legally taken all of the assets years ago - but I believe in what we're doing; I know that our drugs save lives; and I know that many of our shareholders came in because of me. I will not abandon them or the company.
We will succeed - it's not a question of "if", only a question of "when" - and I truly believe that we are very close.
We have no current plans to reverse the stock - certainly not at these ridiculously low valuations. We believe we can see much higher valuations in the coming months with the current share structure.
The company is doing VERY well: we've increased manufacturing capabilities,
> launched six new products, increased online sales, brought on new private
> label customers, created an entire contract manufacturing platform and
> moved forward with our Multiple Sclerosis clinical platform. All this while
> still working with the US government on potential contracts to study our
> nerve agent counter-measures.
>
> Luckily, foreign investors can still purchase our stock and T.Rowe Price
> allows trading in our stock. We've encouraged our shareholders to open
> T.Rowe Price accounts to take advantage of these ridiculously low
> valuations.
>
> So our goal through the rest of this year is to handle the SEC suit - get
> the CE off our symbol and bring our company back to legitimate valuations.
> While we're accomplishing that - - - sales;clinical development; growth
>
> We will endeavor to keep our stakeholders notified as we move our plans
> forward.
>
> As always, Thank you for your interest in Nutra Pharma Corp,
>
Rik
